LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

3.87 -0.51

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.84

Максимум

4.05

Ключови измерители
By Trading Economics
Приходи	-23M -37M
Продажби	-20M 21M
EPS	-0.58
Марж на печалбата	-177.011
Служители	293
EBITDA	-17M -32M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+61.89% upside

Дивиденти
By Dow Jones
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	76M 263M
Предишно отваряне	4.38
Предишно затваряне	3.87

Настроения в новините

By Acuity

50%

161 / 344 Класиране в Healthcare

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.06.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8.06.2026 г., 15:41 ч. UTC

Значими двигатели на пазара

American Battery Shares Jump on Energy Department Victory

8.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rebound After Monday's Selloff -- Market Talk

8.06.2026 г., 23:37 ч. UTC

Пазарно говорене

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8.06.2026 г., 23:25 ч. UTC

Пазарно говорене

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8.06.2026 г., 23:25 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.06.2026 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8.06.2026 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Agrees to Buy m3ter

8.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

8.06.2026 г., 19:22 ч. UTC

Пазарно говорене

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8.06.2026 г., 19:01 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8.06.2026 г., 18:52 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

8.06.2026 г., 18:52 ч. UTC

Пазарно говорене

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8.06.2026 г., 18:17 ч. UTC

Пазарно говорене

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8.06.2026 г., 17:32 ч. UTC

Пазарно говорене

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8.06.2026 г., 17:29 ч. UTC

Пазарно говорене

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8.06.2026 г., 17:29 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.06.2026 г., 16:55 ч. UTC

Придобивния, сливания и поглъщания

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8.06.2026 г., 16:54 ч. UTC

Придобивния, сливания и поглъщания

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8.06.2026 г., 16:40 ч. UTC

Пазарно говорене

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8.06.2026 г., 16:31 ч. UTC

Пазарно говорене

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8.06.2026 г., 16:27 ч. UTC

Пазарно говорене

Mexican Inflation Seen Easing in May -- Market Talk

8.06.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.06.2026 г., 16:03 ч. UTC

Придобивния, сливания и поглъщания

Orange Bought Stake From Lorca

8.06.2026 г., 16:01 ч. UTC

Придобивния, сливания и поглъщания

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8.06.2026 г., 16:01 ч. UTC

Придобивния, сливания и поглъщания

Orange Acquires 100% Ownership of MasOrange

8.06.2026 г., 15:58 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.06.2026 г., 15:58 ч. UTC

Пазарно говорене

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8.06.2026 г., 15:55 ч. UTC

Пазарно говорене

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8.06.2026 г., 15:41 ч. UTC

Пазарно говорене

Gold Falls Below 200-Day Moving Average -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

61.89% нагоре

12-месечна прогноза

Среден 6.33 USD 61.89%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Настроение

By Acuity

161 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.